0.97
-0.0038(-0.39%)
Currency In USD
| Previous Close | 0.97 |
| Open | 0.97 |
| Day High | 0.99 |
| Day Low | 0.95 |
| 52-Week High | 6.98 |
| 52-Week Low | 0.79 |
| Volume | 912,073 |
| Average Volume | 3.36M |
| Market Cap | 43.09M |
| PE | -1.15 |
| EPS | -0.84 |
| Moving Average 50 Days | 1.69 |
| Moving Average 200 Days | 1.69 |
| Change | -0 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $1.42 as of September 29, 2025 at a share price of $0.97. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $72.72 as of September 29, 2025 at a share price of $0.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
GlobeNewswire Inc.
Sep 03, 2025 12:35 PM GMT
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will pr
Outlook Therapeutics Requests Type A Meeting with FDA
GlobeNewswire Inc.
Sep 02, 2025 12:35 PM GMT
ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A M
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
GlobeNewswire Inc.
Aug 28, 2025 10:30 AM GMT
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency’s issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 202